Biopharmaceuticals Market - Growth, Trends, and Forecast (2019 - 2024)

The Biopharmaceuticals Market is segmented by products (monoclonal antibodies, recombinant growth factors, purified proteins, recombinant proteins, recombinant hormones, synthetic immunomodulators, and vaccines), by application, and by geography

Market Snapshot

Biopharmaceuticals Market-1
Study Period:

2016-2024

Base year:

2018

Fastest growing market:

Asia Pacific

Largest market:

North America

Market Size in 2024:

$ 389 Billion

Key Players:

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Market Overview

The global biopharmaceuticals market was valued at USD 237,250.8 million in 2018, and is estimated to be valued at USD 388,997.3 million in 2024, witnessing a CAGR of 8.59%. The market growth is attributed to the growing acceptance for biopharmaceuticals due to their ability to treat previously untreatable diseases, resulting in huge market demand for biopharmaceuticals.

Biopharmaceuticals offer several benefits, such as highly effective and potent action, fewer side effects, and the potential to actually cure diseases rather than merely treat the symptoms, which have significantly increased the demand for biopharmaceutical products.

Biopharmaceuticals have reduced the number of deaths due to cancer and HIV/AIDS in the past decade, which has led to an increase in the adoption of biopharmaceuticals in the global market.

Biopharmaceuticals have given an alternative to the previously less effective and sometimes unsafe treatments, and it allows clinicians to tailor treatments to the specific medical problems experienced by each patient.

Scope of the Report

For the scope of the report, the term biopharmaceutical refers to any biologically synthesized molecule that is used to treat or manage disorders.

By Product Type
Monoclonal Antibodies
Anti Cancer Monoclonal Antibodies
Anti-inflammatory Monoclonal Antibodies
Other Monoclonal Antibodies
Recombinant Growth Factors
Erythropoietin
Granulocyte Colony Stimulating Factor
Purified Proteins
Leukemia Inhibitory Factor (LIF)
P53 Protein
P38 Protein
Other Purified Proteins
Recombinant Proteins
Serum Albumin
Amyloid Protein
Defensin
Transferrin
Recombinant Hormones
Recombinant Hormones
Recombinant Insulin
Other Recombinant Hormones
Vaccines
Recombinant Vaccines
Cancer Vaccines
Malaria Vaccines
Ebola Vaccine
Hepatitis-b Vaccine
Tetanus Vaccine
Diptheria Vaccine
Cholera Vaccine
Other Vaccines
Conventional Vaccines
Polio Vaccine
Pox Vaccine
Other Conventional Vaccines
Recombinant Enzymes
Enterokinase
Cyclase
Caspase
Cathepsin
Cell and Gene Therapies
Allogeneic Products
Autologous Products
Acellular Products
Other Product Types
Blood Factors
Other Product Types
Synthetic Immunomodulators
Cytokines, Interferones, Interleukins
Tumor Necrosis Factor (TNF)
By Therapeutic Application
Oncology
Inflammatory and Infectious Diseases
Autoimmune Disorders
Metabolic Disorders
Hormonal Disorders
Disease Prevention
Cardiovascular Diseases
Neurological Diseases
Other Diseases
Geography
North America
United States
Canada
Mexico
Europe
United Kingdom
Germany
France
Italy
Spain
Rest of Europe
Asia Pacific
India
China
Japan
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Monoclonal Antibodies are Expected to have the Largest Market Size

Among the given segments, monoclonal antibodies are believed to have the largest market size. This can be attributed to the growing research done with the help of monoclonal antibodies. On the other hand, the recombinant enzymes segment is expected to show rapid growth during the forecast period.

Monoclonal antibodies (mAbs) find their application in the areas of cancer treatment. Their use is becoming prevalent in developed countries, such as the United States and the United Kingdom. The mAb drugs in oncology are gaining momentum and growing at a decent pace. The segment is dominating the market currently, and the trend is expected to be followed in the future.

The recombinant enzymes, such as Enterokinase, are gaining attraction because of their efficacy in the digestion of the dietary proteins. Over the years, 100% native protein sequences have been produced using Enterokinase. This application has improved the market scope for this particular enzyme in the recent years.

 

Biopharmaceuticals Market-2

To understand key trends, Download Sample Report

North America is Expected to Dominate the Biopharmaceuticals Market

North America currently dominates the market for biopharmaceuticals, and is expected to continue its stronghold for a few more years. Asia-Pacific is expected to increase its market share in the future owing to increase in the prevalence of diseases, such as diabetes and cancer, along with the regulatory framework that is feasible for the approval of biopharmaceuticals in the region. The United States holds the majority of the market in the North American region; this is due to the increasing prevalence of chronic diseases. In addition, there is a rise in per capita health expenditure in the country that is expected to increase over the forecast period, owing to the decrease in the unemployment rate.

Biopharmaceuticals Market-3

To understand geography trends, Download Sample Report

Competitive Landscape

The biopharmaceuticals market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancement and product innovation, mid-size to smaller companies are increasing their market presence by introducing new products with less prices. Companies, like Amgen Inc., Eli Lily & Company, Johnson & Johnson, and Pfizer Inc. hold a significant share in the biopharmaceuticals market.

Major Players

  1. Abbvie Inc.
  2. Amgen Inc.
  3. Bristol-Myers Squibb Company
  4. Eli Lilly and Company
  5. Johnson & Johnson
  6. Novartis AG

* Complete list of players covered available in the table of contents below

Biopharmaceuticals Market-4

Download the market shares of key players in this industry.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Acceptance for Biopharmaceuticals

      2. 4.2.2 Ability of Biopharmaceuticals to Treat Previously Untreatable Diseases

      3. 4.2.3 Huge Market Demand

    3. 4.3 Market Restraints

      1. 4.3.1 Increasing Demand for Affordable Biopharmaceuticals

      2. 4.3.2 High-end Manufacturing Requirements

      3. 4.3.3 Complicated and Cumbersome Regulatory Requirements

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Product Type

      1. 5.1.1 Monoclonal Antibodies

        1. 5.1.1.1 Anti Cancer Monoclonal Antibodies

        2. 5.1.1.2 Anti-inflammatory Monoclonal Antibodies

        3. 5.1.1.3 Other Monoclonal Antibodies

      2. 5.1.2 Recombinant Growth Factors

        1. 5.1.2.1 Erythropoietin

        2. 5.1.2.2 Granulocyte Colony Stimulating Factor

      3. 5.1.3 Purified Proteins

        1. 5.1.3.1 Leukemia Inhibitory Factor (LIF)

        2. 5.1.3.2 P53 Protein

        3. 5.1.3.3 P38 Protein

        4. 5.1.3.4 Other Purified Proteins

      4. 5.1.4 Recombinant Proteins

        1. 5.1.4.1 Serum Albumin

        2. 5.1.4.2 Amyloid Protein

        3. 5.1.4.3 Defensin

        4. 5.1.4.4 Transferrin

      5. 5.1.5 Recombinant Hormones

        1. 5.1.5.1 Recombinant Hormones

        2. 5.1.5.2 Recombinant Insulin

        3. 5.1.5.3 Other Recombinant Hormones

      6. 5.1.6 Vaccines

        1. 5.1.6.1 Recombinant Vaccines

          1. 5.1.6.1.1 Cancer Vaccines

          2. 5.1.6.1.2 Malaria Vaccines

          3. 5.1.6.1.3 Ebola Vaccine

          4. 5.1.6.1.4 Hepatitis-b Vaccine

          5. 5.1.6.1.5 Tetanus Vaccine

          6. 5.1.6.1.6 Diptheria Vaccine

          7. 5.1.6.1.7 Cholera Vaccine

          8. 5.1.6.1.8 Other Vaccines

        2. 5.1.6.2 Conventional Vaccines

          1. 5.1.6.2.1 Polio Vaccine

          2. 5.1.6.2.2 Pox Vaccine

          3. 5.1.6.2.3 Other Conventional Vaccines

        3. 5.1.6.3 Recombinant Enzymes

          1. 5.1.6.3.1 Enterokinase

          2. 5.1.6.3.2 Cyclase

          3. 5.1.6.3.3 Caspase

          4. 5.1.6.3.4 Cathepsin

        4. 5.1.6.4 Cell and Gene Therapies

          1. 5.1.6.4.1 Allogeneic Products

          2. 5.1.6.4.2 Autologous Products

          3. 5.1.6.4.3 Acellular Products

        5. 5.1.6.5 Other Product Types

          1. 5.1.6.5.1 Blood Factors

          2. 5.1.6.5.2 Other Product Types

      7. 5.1.7 Synthetic Immunomodulators

        1. 5.1.7.1 Cytokines, Interferones, Interleukins

        2. 5.1.7.2 Tumor Necrosis Factor (TNF)

    2. 5.2 By Therapeutic Application

      1. 5.2.1 Oncology

      2. 5.2.2 Inflammatory and Infectious Diseases

      3. 5.2.3 Autoimmune Disorders

      4. 5.2.4 Metabolic Disorders

      5. 5.2.5 Hormonal Disorders

      6. 5.2.6 Disease Prevention

      7. 5.2.7 Cardiovascular Diseases

      8. 5.2.8 Neurological Diseases

      9. 5.2.9 Other Diseases

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 United Kingdom

        2. 5.3.2.2 Germany

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia Pacific

        1. 5.3.3.1 India

        2. 5.3.3.2 China

        3. 5.3.3.3 Japan

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East & Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Abbvie Inc.

      2. 6.1.2 Amgen Inc.

      3. 6.1.3 Bristol-Myers Squibb Company

      4. 6.1.4 Eli Lily & Co.

      5. 6.1.5 Johnson & Johnson

      6. 6.1.6 Novartis AG

      7. 6.1.7 Novo Nordisk Inc.

      8. 6.1.8 Pfizer Inc.

      9. 6.1.9 GlaxoSmithKline PLC

      10. 6.1.10 Roche Holding AG

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please Enter a Valid Message!


Complete your payment details below

Shipping & Billing Information

Payment Information